C. Papavassilis

6.0k total citations · 1 hit paper
51 papers, 4.7k citations indexed

About

C. Papavassilis is a scholar working on Immunology, Dermatology and Physiology. According to data from OpenAlex, C. Papavassilis has authored 51 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Immunology, 24 papers in Dermatology and 11 papers in Physiology. Recurrent topics in C. Papavassilis's work include Psoriasis: Treatment and Pathogenesis (34 papers), Dermatology and Skin Diseases (24 papers) and Asthma and respiratory diseases (10 papers). C. Papavassilis is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (34 papers), Dermatology and Skin Diseases (24 papers) and Asthma and respiratory diseases (10 papers). C. Papavassilis collaborates with scholars based in Germany, Switzerland and United States. C. Papavassilis's co-authors include Richard G. Langley, Bárður Sigurgeirsson, Kristian Reich, Kim Papp, Tsen‐Fang Tsai, C.E.M. Griffiths, Boni E. Elewski, Mark Lebwohl, Hidemi Nakagawa and L. Puig and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Experimental Medicine.

In The Last Decade

C. Papavassilis

49 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

2014 1.5k citations Richard G. Langley, Boni E. Elewski et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by C. Papavassilis

Since Specialization

Citations

This map shows the geographic impact of C. Papavassilis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Papavassilis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Papavassilis more than expected).

Fields of papers citing papers by C. Papavassilis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Papavassilis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Papavassilis. The network helps show where C. Papavassilis may publish in the future.

Co-authorship network of co-authors of C. Papavassilis

This figure shows the co-authorship network connecting the top 25 collaborators of C. Papavassilis. A scholar is included among the top collaborators of C. Papavassilis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Papavassilis. C. Papavassilis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data 2022 ·Acta Dermato Venereologica ·Alice B. Gottlieb, Atul Deodhar, Iain B. McInnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, C. Papavassilis, (unknown), P. Papanastasiou, Philip J. Mease, Mark Lebwohl	57
2	Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies 2018 ·Drugs & Aging ·Andreas Körber, C. Papavassilis, Vaishali Bhosekar, Maximilian Reinhardt	47
3	Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept 2017 ·Journal of the American Academy of Dermatology ·Bruce Strober, Alice B. Gottlieb, Bintu Sherif, Patrick Mollon, I. Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, C. Papavassilis, Mark Lebwohl	19
4	Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab 2017 ·Journal of Dermatological Treatment ·Boni E. Elewski, L. Puig, Margaret Mordin, I. Gilloteau, Bintu Sherif, Todd Fox, Ari Gnanasakthy, C. Papavassilis, Bruce Strober	49
5	Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study 2017 ·British Journal of Dermatology ·Robert Bissonnette, Thomas A. Luger, Diamant Thaçi, D. Toth, I. Messina, R. You, Adriana Guana, T. Fox, C. Papavassilis, I. Gilloteau, Ulrich Mrowietz	55
6	Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials 2016 ·International Journal of Dermatology ·Bruce Strober, Bárður Sigurgeirsson, Georg Popp, Rodney Sinclair, James Krell, (unknown), (unknown), Boni E. Elewski, Alice B. Gottlieb, Yang Zhao, Mary Helen Tran, (unknown), Lori McLeod, Margaret Mordin, C. Papavassilis, Judit Nyirady, Mark Lebwohl	37
7	Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE) 2015 ·Journal of the American Academy of Dermatology ·Ulrich Mrowietz, Craig L. Leonardi, Giampiero Girolomoni, Darryl Toth, Akimichi Morita, (unknown), Jacek C. Szepietowski, P. Regnault, (unknown), C. Papavassilis	170
8	Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials breakdown → 2014 ·New England Journal of Medicine ·Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, (unknown), Silvia Helou, C. Papavassilis	1488
9	Secukinumab efficacy and safety in Japanese patients with moderate‐to‐severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo‐controlled, phase 3 study 2014 ·The Journal of Dermatology ·Mamitaro Ohtsuki, Akimichi Morita, Masatoshi Abe, Hidetoshi Takahashi, Noriko Seko, (unknown), (unknown), C. Papavassilis, Hidemi Nakagawa, (unknown)	75
10	Item-Level Psychometric Properties for a New Patient-Reported Psoriasis Symptom Diary 2013 ·Value in Health ·Bruce Strober, Judit Nyirady, Usha G. Mallya, Achim Guettner, C. Papavassilis, Alice B. Gottlieb, Boni E. Elewski, Diane M. Turner‐Bowker, Alan L. Shields, Chad Gwaltney, Mark Lebwohl	22
11	Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study 2012 ·British Journal of Dermatology ·Kim Papp, Richard G. Langley, Bárður Sigurgeirsson, Masatoshi Abe, Donald R Baker, Pille Konno, Sibylle Haemmerle, (unknown), C. Papavassilis, H. Richards	296
12	Schnell wachsender, erodierter Knoten am Ohrläppchen 2008 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·C. Papavassilis, Elemir Macedo de Souza, Eva‐B. Bröcker, Michael P. Schön	1
13	Medium-chain triglycerides inhibit growth of Malassezia: Implications for prevention of systemic infection 1999 ·Critical Care Medicine ·C. Papavassilis, (unknown), Peter Mayser	22
14	Growth requirements and nitrogen metabolism of Malassezia furfur 1998 ·Archives of Dermatological Research ·Peter Mayser, (unknown), (unknown), C. Papavassilis	16
15	Acceleration of experimental diabetic retinopathy in the rat by omega-3 fatty acids 1996 ·Diabetologia ·H. P. Hammes, (unknown), (unknown), (unknown), C. Papavassilis, Friedrich Grimminger	32
16	Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. 1996 ·The Journal of Experimental Medicine ·Friedrich Grimminger, Katja Hattar, C. Papavassilis, Bettina Temmesfeld‐Wollbrück, Elena Csernok, Wolfgang L. Gross, Werner Seeger, Ulf Sibelius	61
17	Hydrolase activity of 150 Malassezia furfur isolates of different clinical origin 1996 ·Mycoses ·Peter Mayser, Christoph Scheurer, C. Papavassilis, (unknown)	6
18	Hefen der Gattung Trichosporon Identifizierung, Epidemiologie und Bedeutung der dermatologischen Krankheitsbilder 1996 ·Der Hautarzt ·Peter Mayser, (unknown), C. Papavassilis, (unknown)	11
19	[Immunosuppressive effect of parenteral fat emulsions in defined immunostimulation]. 1995 ·PubMed ·H. Grimm, A Tibell, (unknown), (unknown), (unknown), C. Papavassilis, D Führer, Karl Mayer, Friedrich Grimminger	4
20	Influence of intravenous n‐3 lipid supplementation on fatty acid profiles and lipid mediator generation in a patient with severe ulcerative colitis 1993 ·European Journal of Clinical Investigation ·Friedrich Grimminger, D Führer, C. Papavassilis, E. Schlotzer, Konstantin Mayer, (unknown), Levente Kiss, D. Walmrath, (unknown), Friedrich Lübbecke, H. J. Kramer, Jan F. Stevens, G Schütterle, Werner Seeger	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact